New Taiho, Cullian data heats up lung cancer drug battle
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.